Phase 3 Recruiting Network
This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are bei…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03418961
Sites in Arkansas: - CHI Saint Vincent Cancer Center Hot Springs — Hot Springs, Arkansas
Phase 3 Recruiting NIH
This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated low-grade glioma (LGG) that does not have…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04166409
Sites in Arkansas: - Arkansas Children's Hospital — Little Rock, Arkansas
Phase 3 Recruiting Network
This phase III trial tests two hypotheses in patients with low-risk and average-risk medulloblastoma. Medulloblastoma is a type of cancer that occurs in the back of the brain. The term, risk, refers to the chance of the cancer coming back …
Sponsor: Children's Oncology Group
NCT ID: NCT05382338
Sites in Arkansas: - Arkansas Children's Hospital — Little Rock, Arkansas
Phase 2 Recruiting Network
This phase II trial compares the effect of encorafenib, binimetinib, and nivolumab versus ipilimumab and nivolumab in treating patients with BRAF- V600 mutant melanoma that has spread to the brain (brain metastases). Encorafenib and binime…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT04511013
Sites in Arkansas: - Mercy Hospital Fort Smith — Fort Smith, Arkansas
Phase 2 Recruiting Network
This phase II trial studies the best approach to combine chemotherapy and radiation therapy (RT) based on the patient's response to induction chemotherapy in patients with non-germinomatous germ cell tumors (NGGCT) that have not spread to …
Sponsor: Children's Oncology Group
NCT ID: NCT04684368
Sites in Arkansas: - Arkansas Children's Hospital — Little Rock, Arkansas
Phase 1, Phase 2 Recruiting NIH
This phase I/II trial tests the safety, side effects, and best dose of selinexor given in combination with standard radiation therapy in treating children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG) or hig…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05099003
Sites in Arkansas: - Arkansas Children's Hospital — Little Rock, Arkansas
Phase 2 Recruiting Industry
The purpose of this study is to see if combining silevertinib with temozolomide after surgery and radiotherapy helps treat newly diagnosed glioblastoma (GBM) better than using temozolomide alone in the maintenance setting. Specifically, th…
Sponsor: Black Diamond Therapeutics, Inc.
NCT ID: NCT07326566
Sites in Arkansas: - Highlands Oncology Group — Springdale, Arkansas
Phase 2 Recruiting Academic/Other
Difluoromethylornithine (DFMO) will be used in an open label, multicenter, study as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma.
Sponsor: Giselle Sholler
NCT ID: NCT04696029
Sites in Arkansas: - Arkansas Children's Hospital — Little Rock, Arkansas
Phase 1, Phase 2 Recruiting Academic/Other
The purpose of this study is to evaluate the investigational oral drug AMXT 1501 in combination with oral eflornithine (DFMO). An investigational drug is one that has not been approved by the U.S. Food \& Drug Administration (FDA), or any …
Sponsor: Milton S. Hershey Medical Center
NCT ID: NCT06465199
Sites in Arkansas: - Arkansas Children's Hospital — Little Rock, Arkansas
Phase 1, Phase 2 Recruiting Industry
An open label, non-randomized study in pediatric patients with advanced high-grade gliomas and other solid tumors. The study will be performed in two phases: a dose escalation phase in up to 18 patients following a standard "3+3" design to…
Sponsor: Laminar Pharmaceuticals
NCT ID: NCT04299191
Sites in Arkansas: - Arkansas Children's Research Institute — Little Rock, Arkansas
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Arkansas: - Massive Bio SYNERGY-AI site — Little Rock, Arkansas
Recruiting Industry
The objectives of this registry study are to evaluate real-world clinical outcomes and patient reported outcomes that measure the effectiveness and safety of STaRT.
Sponsor: GT Medical Technologies, Inc.
NCT ID: NCT04427384
Sites in Arkansas: - University of Arkansas Medical Center — Little Rock, Arkansas